PMID- 26986169
OWN - NLM
STAT- MEDLINE
DCOM- 20160802
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 11
DP  - 2016 Mar
TI  - The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 
      Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials 
      Following the PRISMA Guidelines.
PG  - e3134
LID - 10.1097/MD.0000000000003134 [doi]
LID - e3134
AB  - The purpose of this study was to investigate the efficacy and safety of 
      programmed cell death 1 (PD-1) and programmed cell death 1 ligand (PD-L1) 
      inhibitors using a meta-analysis of present trials for advanced melanoma. A fully 
      recursive literature search of the primary electronic databases for available 
      trials was performed. The objective response rate (ORR) and the median 
      progression-free survival (PFS) of clinical responses were considered the main 
      endpoints to evaluate the efficacy, whereas Grade 3-4 adverse effects (AEs) were 
      analyzed to evaluate safety. The ORR of PD-1 and PD-L1 inhibitors was 30% (95% 
      CI: 25-35%). No significant difference in the ORR was observed after the 
      comparisons of low-dose, median-dose, and high-dose cohorts. In addition, the 
      rate of Grade 3-4 AEs was 9% (95% CI: 6-12%). According to the 3 randomized 
      controlled trials that compared PD-1 inhibitors with chemotherapy, the difference 
      between these 2 groups was found to be statistically significant with respect to 
      the ORR, PFS and the incidence of Grade 3-4 AEs; that is, the relative risk (RR) 
      of the ORR was 3.42 (95% CI: 2.49-4.69, P < 0.001), the hazard ratio (HR) of the 
      PFS was 0.50 (95% CI: 0.44-0.58, P < 0.001), and the RR of Grade 3-4 AEs was 0.45 
      (95% CI: 0.31-0.65, P < 0.001). According to a meta-analysis of limited 
      concurrent studies, PD-1 and PD-L1 inhibitors appear to be associated with 
      improved response rates, superior response durability and tolerable toxicity in 
      patients with advanced melanoma.
FAU - Guan, Xiuwen
AU  - Guan X
AD  - From the Department of Medical Oncology (XG, FM, ZY, BX), and State Key 
      Laboratory of Molecular Oncology (HW, HQ), Cancer Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Wang, Haijuan
AU  - Wang H
FAU - Ma, Fei
AU  - Ma F
FAU - Qian, Haili
AU  - Qian H
FAU - Yi, Zongbi
AU  - Yi Z
FAU - Xu, Binghe
AU  - Xu B
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
RN  - B932PAQ1BQ (pidilizumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - B7-H1 Antigen/*antagonists & inhibitors
MH  - Clinical Trials as Topic
MH  - Disease-Free Survival
MH  - Humans
MH  - Melanoma/*drug therapy
MH  - Nivolumab
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Treatment Outcome
PMC - PMC4839950
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2016/03/18 06:00
MHDA- 2016/08/03 06:00
PMCR- 2016/03/18
CRDT- 2016/03/18 06:00
PHST- 2016/03/18 06:00 [entrez]
PHST- 2016/03/18 06:00 [pubmed]
PHST- 2016/08/03 06:00 [medline]
PHST- 2016/03/18 00:00 [pmc-release]
AID - 00005792-201603150-00076 [pii]
AID - 10.1097/MD.0000000000003134 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Mar;95(11):e3134. doi: 10.1097/MD.0000000000003134.